Research Corporation Technologies

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

S2 Genomics, Inc. is a biotechnology company that specializes in developing integrated sample preparation systems for genomic analyses. Founded in 2016 and headquartered in Livermore, California, the company focuses on spatial sequencing technology that captures the three-dimensional coordinates of single cells within tissues. S2 Genomics' solutions automate the processing of solid tissues into single cells or nuclei, which enhances the efficiency and reproducibility of genomic studies. By enabling researchers to isolate viable cells with minimal impact on the cellular transcriptome, the company aims to improve the quality and quantity of samples available for genomics and cell biology research.

iotaMotion, Inc. is a company focused on developing and manufacturing innovative cochlear ear implants to address hearing loss. Established in 2015 and based in Iowa City, Iowa, iotaMotion offers a robotic-assisted surgical system that standardizes the insertion of cochlear implant electrodes. This system is designed to enhance accessibility for both surgeons and patients, effectively reducing surgical variability by controlling the speed and acceleration of electrode insertion. By personalizing the insertion approach, iotaMotion enables healthcare professionals to deliver more precise and individualized cochlear intervention treatments, ultimately improving patient outcomes in hearing restoration.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell Inc. is a biotechnology company based in Beverly, Massachusetts, specializing in sequencing services and library preparation workflows. Founded in 2014, seqWell offers a range of products, including paramagnetic beads for nucleic acid purification and library preparation kits. The company has developed a transformative technology platform that enables simple and scalable multiplexing of hundreds to thousands of samples, significantly reducing the time and costs associated with normalization. In addition to its products, seqWell provides comprehensive biological library preparation, sequencing, data processing, and customized bioinformatics support services. Its offerings are distributed in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels.

Pheon Therapeutics is a London-based biotechnology company specializing in the development of Antibody-Drug Conjugates (ADCs) for challenging cancer types. Founded in 2022, the company focuses on creating a novel pipeline of next-generation ADCs designed to target solid tumors that are often resistant to existing treatments. Its lead program features a first-in-class ADC aimed at a unique target that is highly expressed in various hard-to-treat cancers. By advancing these innovative therapies, Pheon Therapeutics aims to provide effective treatment options for patients and healthcare providers facing the complexities of cancer management.

Q'Apel Medical is a medical device company based in Fremont, California, established in 2016. The company specializes in developing access device technology aimed at addressing unmet clinical needs in neurovascular interventions. Its innovative devices facilitate endovascular treatments for conditions such as stroke and cerebral aneurysms, enhancing physicians' ability to navigate complex neurovascular pathways. By improving trackability and access during procedures, Q'Apel Medical's offerings aim to enhance clinical efficacy and patient outcomes in the field of neurovascular care.

Translational Drug Development, LLC is a biotechnology company specializing in preclinical services for oncology medicine development. Founded in 2003 and located in Scottsdale, Arizona, the company focuses on providing comprehensive support for oncology-focused enterprises. Its offerings include regulatory strategic guidance, planning and document submission services, as well as clinical trial design and execution. By conducting clinical programs that identify unique contexts of sensitivity for new cancer treatments, Translational Drug Development enables researchers to enhance the effectiveness of drug development and expedite patient benefits during clinical testing. This approach positions the company as a key player in advancing oncology research and improving therapeutic outcomes for cancer patients.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell Inc. is a biotechnology company based in Beverly, Massachusetts, specializing in sequencing services and library preparation workflows. Founded in 2014, seqWell offers a range of products, including paramagnetic beads for nucleic acid purification and library preparation kits. The company has developed a transformative technology platform that enables simple and scalable multiplexing of hundreds to thousands of samples, significantly reducing the time and costs associated with normalization. In addition to its products, seqWell provides comprehensive biological library preparation, sequencing, data processing, and customized bioinformatics support services. Its offerings are distributed in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

BioInformatics LLC is a market research and advisory company established in 1994, headquartered in Arlington, Virginia. It serves the life science, medical device, pharmaceutical, and diagnostic industries globally. The company specializes in assessing market size and attractiveness, optimizing product configurations and pricing strategies, validating corporate acquisitions, measuring brand loyalty, evaluating brand strength and positioning, and forecasting markets and technologies. BioInformatics offers custom research services such as product concept testing, customer satisfaction analysis, market attractiveness studies, and brand awareness assessments. Its clients include biotechnology companies, medical diagnostics firms, pharmaceutical corporations, professional services providers, publishers, and associations. The company's team comprises industry veterans, market research experts, consultants, and survey statisticians.

AustinPx is a contract development and manufacturing organization specializing in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides a range of preclinical services through Phase II formulation and process development, along with the GMP manufacturing of oral dosage forms. By focusing on the development of novel therapeutics from poorly bioavailable drugs, AustinPx enables healthcare providers to enhance clinical outcomes for patients.

OrthAlign, Inc., established in 2004 and headquartered in Aliso Viejo, California, is a medical device company specializing in surgical navigation products for precise alignment in orthopedic procedures. The company offers handheld navigation devices for knee and hip arthroplasty surgeries, including KneeAlign for total knee replacement, HipAlign for cup placement and leg length measurement, and UniAlign for unicompartmental knee arthroplasty. OrthAlign's products serve orthopedic surgeons, hospitals, and patients worldwide through a network of distributors, aiming to improve patient outcomes by providing consistent, measurable results in joint replacement surgeries.

Rubicon Genomics, Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in nucleic acid library preparation and amplification technologies that facilitate sensitive analysis of clinical research samples. Founded in 2000 by University of Michigan faculty members, the company focuses on advancing the application of human genetics to practical medicine. Rubicon Genomics offers a range of products, including the ThruPLEX and PicoPLEX kits, which utilize ligation-based and quasi-random primed amplification methods to enhance DNA sequencing and analysis. The company's innovative technologies also include tests designed to detect DNA methylation patterns in cancer cells, providing non-invasive diagnostic options. Rubicon sells its products directly and through distributors, catering to both research and commercial markets, and is committed to supporting the local Michigan economy.

CyMedica Orthopedics, Inc. is a medical device company focused on developing and commercializing innovative products for joint injuries and the associated muscle atrophy. Founded in 2013 and based in Scottsdale, Arizona, CyMedica offers a range of orthopedic solutions that utilize proprietary neuromuscular electrical stimulation technology. Its flagship product, e-vive, provides individualized muscle stimulation therapy through a wireless and app-controlled system, allowing patients to engage in their rehabilitation while tracking progress and sharing data with clinicians. Additionally, the company offers a variety of products, including the Conductive garment, which ensures effective muscle activation, the ACL Brace for post-operative support, and The QB1 System, designed to empower patients in overcoming quadricep weakness. These devices aim to stabilize joints, prevent muscle weakening during recovery, and improve patient outcomes while reducing the likelihood of readmission.

AustinPx is a contract development and manufacturing organization specializing in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides a range of preclinical services through Phase II formulation and process development, along with the GMP manufacturing of oral dosage forms. By focusing on the development of novel therapeutics from poorly bioavailable drugs, AustinPx enables healthcare providers to enhance clinical outcomes for patients.

Providence Medical Technology, Inc. is a medical device company specializing in innovative solutions for cervical spine conditions, operating in the United States and internationally. The company has developed a proprietary approach to cervical fusion, offering a range of products designed to treat cervical degenerative disc disease through indirect decompression and fusion. Its product lineup includes the DTRAX Spinal System, which comprises single-use disposable instruments for accessing the spine via posterior surgical incisions; the DTRAX Cervical Cage for treating cervical radiculopathy; the DTRAX Graft, a structural allograft for supporting posterior fusion; and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

ClearFlow, Inc. is a medical device company focused on developing technologies to address clinical challenges related to obstructed catheters. The company specializes in active blood and fluid evacuation systems, with its flagship product, the PleuraFlow Active Clearance Technology, designed to maintain chest tube patency following cardiothoracic surgery. This system effectively prevents the retention of blood and fluids in the chest cavity, thereby reducing the risk of post-surgical complications. ClearFlow’s proprietary technology is also being adapted for use in various medical segments, including urinary and gastrointestinal catheters, as well as wound drainage systems. Founded in 2006 and headquartered in Anaheim, California, ClearFlow aims to enhance patient recovery processes and overall surgical outcomes by ensuring optimal catheter performance. The company also operates a service center in Maastricht, the Netherlands.

OrthAlign, Inc., established in 2004 and headquartered in Aliso Viejo, California, is a medical device company specializing in surgical navigation products for precise alignment in orthopedic procedures. The company offers handheld navigation devices for knee and hip arthroplasty surgeries, including KneeAlign for total knee replacement, HipAlign for cup placement and leg length measurement, and UniAlign for unicompartmental knee arthroplasty. OrthAlign's products serve orthopedic surgeons, hospitals, and patients worldwide through a network of distributors, aiming to improve patient outcomes by providing consistent, measurable results in joint replacement surgeries.

OrthAlign, Inc., established in 2004 and headquartered in Aliso Viejo, California, is a medical device company specializing in surgical navigation products for precise alignment in orthopedic procedures. The company offers handheld navigation devices for knee and hip arthroplasty surgeries, including KneeAlign for total knee replacement, HipAlign for cup placement and leg length measurement, and UniAlign for unicompartmental knee arthroplasty. OrthAlign's products serve orthopedic surgeons, hospitals, and patients worldwide through a network of distributors, aiming to improve patient outcomes by providing consistent, measurable results in joint replacement surgeries.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments by modifying and repurposing existing drugs. Headquartered in Weston, Florida, the company is advancing two primary development programs that utilize established therapies to create safer and more effective treatments for various types of cancer, including metastatic breast cancer, pancreatic cancer, and glioblastoma. Among its notable offerings are ODSH, a low anticoagulant heparin derivative designed to mitigate chemotherapy-induced reductions in platelet counts, and Disulfiram-Copper Chelate, which employs distinct mechanisms targeting cancer stem cells to combat tumor progression. Founded in 2002, Cantex Pharmaceuticals aims to address significant unmet medical needs in oncology, positioning itself within high-value market opportunities.

CryoFluor Therapeutics engages in the development of medical devices to treat various diseases using a liquid cryogenic technology.

Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments by modifying and repurposing existing drugs. Headquartered in Weston, Florida, the company is advancing two primary development programs that utilize established therapies to create safer and more effective treatments for various types of cancer, including metastatic breast cancer, pancreatic cancer, and glioblastoma. Among its notable offerings are ODSH, a low anticoagulant heparin derivative designed to mitigate chemotherapy-induced reductions in platelet counts, and Disulfiram-Copper Chelate, which employs distinct mechanisms targeting cancer stem cells to combat tumor progression. Founded in 2002, Cantex Pharmaceuticals aims to address significant unmet medical needs in oncology, positioning itself within high-value market opportunities.

NP Photonics, Inc. develops and manufactures specialty fiber lasers, fiber amplifiers, and transport fibers primarily for the near- and mid-infrared wavelength bands. Founded in 1998 and based in Tucson, Arizona, the company offers a range of products, including micron fiber lasers, multi-channel fiber laser systems, and mid-infrared transport fibers. These products are utilized across various applications such as acoustic sensing, LIDAR, coherent communication, and environmental seeding. NP Photonics serves markets including sensing, defense, metrology, and research through a network of distributors and sales representatives in several countries, including Australia, Europe, and Asia. The company, previously known as NP Photonic Technologies, LLC, changed its name in August 2000.